Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464086 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 6, 1, 5, 9, 6 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).

- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Neutropenia - Overview

Chemotherapy Induced Neutropenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chemotherapy Induced Neutropenia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development

BeyondSpring Inc

Biocon Ltd

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Dr. Reddy's Laboratories Ltd

Enzychem Lifesciences Corp

Gene Techno Science Co Ltd

Generon (Shanghai) Corp Ltd

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

Lupin Ltd

Mycenax Biotech Inc

Nohla Therapeutics Inc

Pangen Biotech Inc

Pfizer Inc

PharmaEssentia Corp

Profarma

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Tanvex BioPharma Inc

USV Pvt Ltd

Valenta Pharm

Chemotherapy Induced Neutropenia - Drug Profiles

BBT-007 - Drug Profile

BBT-015 - Drug Profile

Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile

dilanubicel - Drug Profile

eflapegrastim - Drug Profile

F-627 - Drug Profile

filgrastim - Drug Profile

GR-007 - Drug Profile

GW-003 - Drug Profile

GXG-3 - Drug Profile

lenograstim - Drug Profile

mosedipimod - Drug Profile

Myelo-001 - Drug Profile

pegfilgrastim - Drug Profile

plinabulin - Drug Profile

romyelocel-L - Drug Profile

SFR-9314 - Drug Profile

UB-853 - Drug Profile

uproleselan sodium - Drug Profile

YPEG-Filgrastim - Drug Profile

Chemotherapy Induced Neutropenia - Dormant Projects

Chemotherapy Induced Neutropenia - Discontinued Products

Chemotherapy Induced Neutropenia - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464086 | GMDHC11422IDB

Number of Pages

137

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
31-03-2017

$2,000 USD

Published by Global Markets Direct
31-03-2017

$2,000 USD

Published by Global Markets Direct
08-03-2017

$2,000 USD

Published by Global Markets Direct
08-03-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.